Revvity Inc (RVTY)

$119.25

-0.42

(-0.35%)▲

Market is closed - opens 7 PM, 22 Oct 2024

Performance

  • $117.83
    $119.48
    $119.25
    downward going graph

    1.19%

    Downside

    Day's Volatility :1.38%

    Upside

    0.19%

    downward going graph
  • $79.50
    $128.15
    $119.25
    downward going graph

    33.33%

    Downside

    52 Weeks Volatility :37.96%

    Upside

    6.94%

    downward going graph

Returns

PeriodRevvity IncS&P500
3 Months
8.11%
5.2%
6 Months
18.76%
16.8%
1 Year
17.0%
38.6%
3 Years
-32.2%
28.8%

Highlights

Market Capitalization
14.8B
Book Value
$63.80
Dividend Share
0.28
Dividend Yield
0.23%
Earnings Per Share (EPS)
1.6
PE Ratio
74.79
PEG Ratio
3.03
Wall Street Target Price
139.45
Profit Margin
6.26%
Operating Margin TTM
15.05%
Return On Assets TTM
1.59%
Return On Equity TTM
2.51%
Revenue TTM
2.7B
Revenue Per Share TTM
21.92
Quarterly Revenue Growth YOY
-2.5%
Gross Profit TTM
2.0B
EBITDA
781.4M
Diluted Eps TTM
1.6
Quarterly Earnings Growth YOY
0.58
EPS Estimate Current Year
4.75
EPS Estimate Next Year
5.17
EPS Estimate Current Quarter
1.12
EPS Estimate Next Quarter
1.14

Analyst Recommendation

Buy
    64%Buy
    36%Hold
    0
    0%Sell
Based on 25 Wall street analysts offering stock ratings for Revvity Inc(by analysts ranked 0 to 5 stars)
Based on 25 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
16
Hold
9
9
9
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 16.94%

Current $119.25
Target $139.45

Company Financials

FY18Y/Y Change
Revenue
2.8B
↑ 23.08%
Net Income
237.9M
↑ 51.65%
Net Profit Margin
8.56%
↑ 1.61%
FY19Y/Y Change
Revenue
2.9B
↑ 3.8%
Net Income
227.6M
↓ 4.36%
Net Profit Margin
7.89%
↓ 0.67%
FY20Y/Y Change
Revenue
3.8B
↑ 31.18%
Net Income
727.9M
↑ 219.87%
Net Profit Margin
19.24%
↑ 11.35%
FY21Y/Y Change
Revenue
5.1B
↑ 33.95%
Net Income
943.2M
↑ 29.57%
Net Profit Margin
18.61%
↓ 0.63%
FY22Y/Y Change
Revenue
3.3B
↓ 34.64%
Net Income
569.2M
↓ 39.65%
Net Profit Margin
17.19%
↓ 1.42%
FY23Y/Y Change
Revenue
2.8B
↓ 16.95%
Net Income
179.5M
↓ 68.46%
Net Profit Margin
6.53%
↓ 10.66%
Q1 FY23Q/Q Change
Revenue
674.9M
↓ 8.95%
Net Income
24.8M
↓ 80.54%
Net Profit Margin
3.68%
↓ 13.54%
Q2 FY23Q/Q Change
Revenue
709.1M
↑ 5.07%
Net Income
35.6M
↑ 43.12%
Net Profit Margin
5.01%
↑ 1.33%
Q3 FY23Q/Q Change
Revenue
670.7M
↓ 5.41%
Net Income
9.5M
↓ 73.29%
Net Profit Margin
1.42%
↓ 3.59%
Q4 FY23Q/Q Change
Revenue
695.9M
↑ 3.75%
Net Income
78.6M
↑ 727.24%
Net Profit Margin
11.29%
↑ 9.87%
Q1 FY24Q/Q Change
Revenue
649.9M
↓ 6.61%
Net Income
26.0M
↓ 66.89%
Net Profit Margin
4.0%
↓ 7.29%
Q2 FY24Q/Q Change
Revenue
691.7M
↑ 6.43%
Net Income
79.1M
↑ 204.11%
Net Profit Margin
11.44%
↑ 7.44%
FY18Y/Y Change
Total Assets
6.0B
↓ 1.91%
Total Liabilities
3.4B
↓ 5.51%
FY19Y/Y Change
Total Assets
6.5B
↑ 9.52%
Total Liabilities
3.7B
↑ 10.03%
FY20Y/Y Change
Total Assets
8.0B
↑ 22.4%
Total Liabilities
4.3B
↑ 14.58%
FY21Y/Y Change
Total Assets
15.0B
↑ 87.45%
Total Liabilities
7.9B
↑ 84.46%
FY22Y/Y Change
Total Assets
14.1B
↓ 5.92%
Total Liabilities
6.7B
↓ 14.6%
FY23Y/Y Change
Total Assets
13.6B
↓ 3.98%
Total Liabilities
5.7B
↓ 15.47%
Q1 FY23Q/Q Change
Total Assets
14.6B
↑ 3.62%
Total Liabilities
6.6B
↓ 1.93%
Q2 FY23Q/Q Change
Total Assets
14.2B
↓ 2.87%
Total Liabilities
6.3B
↓ 3.87%
Q3 FY23Q/Q Change
Total Assets
13.4B
↓ 5.61%
Total Liabilities
5.7B
↓ 9.79%
Q4 FY23Q/Q Change
Total Assets
13.6B
↑ 1.07%
Total Liabilities
5.7B
↓ 0.62%
Q1 FY24Q/Q Change
Total Assets
13.4B
↓ 0.97%
Total Liabilities
5.6B
↓ 1.86%
Q2 FY24Q/Q Change
Total Assets
13.4B
↓ 0.06%
Total Liabilities
5.6B
↓ 0.57%
FY19Y/Y Change
Operating Cash Flow
363.5M
↑ 16.86%
Investing Cash Flow
-487.6M
-
Financing Cash Flow
150.1M
↓ 183.76%
FY20Y/Y Change
Operating Cash Flow
892.2M
↑ 145.46%
Investing Cash Flow
-504.5M
↑ 3.47%
Financing Cash Flow
-202.9M
↓ 235.13%
FY21Y/Y Change
Operating Cash Flow
1.4B
↑ 58.12%
Investing Cash Flow
-4.1B
↑ 715.22%
Financing Cash Flow
2.9B
↓ 1550.01%
FY22Y/Y Change
Operating Cash Flow
679.8M
↓ 51.81%
Investing Cash Flow
-132.9M
↓ 96.77%
Financing Cash Flow
-661.8M
↓ 122.5%
Q1 FY23Q/Q Change
Operating Cash Flow
63.5M
↓ 54.4%
Investing Cash Flow
-571.0M
↑ 2123.33%
Financing Cash Flow
-113.2M
↑ 47.58%
Q2 FY23Q/Q Change
Operating Cash Flow
-135.3M
↓ 313.23%
Investing Cash Flow
-571.0M
↑ 0.0%
Financing Cash Flow
-228.3M
↑ 101.68%
Q3 FY23Q/Q Change
Operating Cash Flow
-33.5M
↓ 75.25%
Investing Cash Flow
434.9M
↓ 176.15%
Financing Cash Flow
-586.0M
↑ 156.73%

Technicals Summary

Sell

Neutral

Buy

Revvity Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Revvity Inc
Revvity Inc
-1.97%
18.76%
17.0%
-32.2%
42.29%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-9.83%
-4.55%
7.02%
-29.06%
64.14%
Agilent Technologies Inc.
Agilent Technologies Inc.
-0.69%
3.67%
26.97%
-11.54%
83.93%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-1.42%
9.73%
30.29%
-1.67%
114.14%
Danaher Corp.
Danaher Corp.
0.45%
16.22%
34.47%
-11.7%
98.5%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-1.68%
2.31%
28.84%
-7.12%
65.36%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Revvity Inc
Revvity Inc
74.41
74.79
3.03
4.75
0.03
0.02
0.0
63.8
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
45.68
45.46
4.82
10.56
0.63
0.23
NA
19.16
Agilent Technologies Inc.
Agilent Technologies Inc.
28.86
28.49
2.99
5.24
0.25
0.08
0.01
20.53
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.11
37.3
2.24
21.72
0.14
0.05
0.0
124.17
Danaher Corp.
Danaher Corp.
50.0
50.53
2.71
7.58
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
30.78
30.78
1.16
11.19
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Revvity Inc
Revvity Inc
Buy
$14.7B
42.29%
74.41
6.26%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$37.9B
64.14%
45.68
22.34%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$39.9B
83.93%
28.86
21.75%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$228.9B
114.14%
37.11
14.69%
Danaher Corp.
Danaher Corp.
Buy
$196.4B
98.5%
50.0
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$43.1B
65.36%
30.78
9.39%

Insights on Revvity Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 649.92M → 691.68M (in $), with an average increase of 6.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 26.01M → 79.10M (in $), with an average increase of 67.1% per quarter

  • Vs DHR

    In the last 1 year, Danaher Corp. has given 32.2% return, outperforming this stock by 14.9%

  • Vs TMO

    In the last 3 years, Revvity Inc has experienced a drawdown of -32.4%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 19.2%

Corporate Announcements

  • Revvity Inc Dividends March,2024

    In the quarter ending March,2024. Revvity Inc has declared dividend of $0.07

    Read More

Company Information

as a leader focused on improving human and environmental health, we are helping scientists, clinicians, and government agencies discover more effective diagnostics and therapies, and making sure that the food we eat and the air we breathe are safe from contaminants. environmental health overview at perkinelmer, we’re taking action to ensure the quality of our environment. the ability to rapidly detect known and unknown contaminants in our food, water and air, or to monitor their quality consistently, is an important part of maintaining a healthy environment. our systems and services help scientists understand all of these complexities and ensure compliance. from food safety to air & water quality, perkinelmer transforms information into results that improve our health and safety today and our world tomorrow. human health overview perkinelmer creates life science research and diagnostic instrumentation as well as informatics and diagnostic lab services—all to fight illness proacti

Organization
Revvity Inc
Employees
11000
CEO
Dr. Prahlad R. Singh Ph.D.
Industry
Miscellaneous

Discover More

FAQs